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Abstract
 
Vertebrates express three cytokine-inducible proteasome subunits that are incorporated in the
place of their constitutively synthesized counterparts. There is increasing evidence that the set of
peptides generated by proteasomes containing these subunits (immunoproteasomes) differs from
that produced by standard proteasomes. In this study, we use mice lacking one of the immuno-
proteasome subunits (LMP2) to show that immunoproteasomes play an important role in estab-
 
lishing the immunodominance hierarchy of CD8
 
 
 
 T cells (T
 
CD8
 
 
 
) responding to seven defined
determinants in influenza virus. In LMP2
 
 
 
/
 
 
 
 mice, responses to the two most dominant deter-
minants drop precipitously, whereas responses to two subdominant determinants are greatly en-
hanced. Adoptive transfer experiments with naive normal and transgenic T
 
CD8
 
 
 
 reveal that the
reduced immunogenicity of one determinant (PA
 
224–233
 
) can be attributed to decreased genera-
tion by antigen presenting cells (APCs), whereas the other determinant (NP
 
366–374
 
) is less immu-
nogenic due to alterations in the T
 
CD8
 
 
 
 repertoire, and not, as reported previously, to the de-
creased capacity of LMP2
 
 
 
/
 
 
 
 APCs to generate the determinant. The enhanced response to one
 
of the subdominant determinants (PB1F2
 
62–70
 
) correlates with increased generation by LMP2
 
 
 
/
 
 
 
virus–infected cells. These findings indicate that in addition to their effects on the presentation
of foreign antigens, immunoproteasomes influence T
 
CD8
 
 
 
 responses by modifying the repertoire
of responding T
 
CD8
 
 
 
.
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Introduction
 
Proteasomes are multicatalytic enzymes complexes that are
responsible for the turnover of most cellular proteins and
also for the generation of the bulk of antigenic peptides
transported by transporter associated with antigen presenta-
tion (TAP) and presented by MHC class I molecules (1).
26S proteasomes consists of catalytic 20S proteasomes and
either the 19S or 11S regulatory complexes. The 20S pro-
teasome is a four-ring structure with seven different sub-
units in each ring, arrayed as 
 
 
 
7
 
 
 
7
 
 
 
7
 
 
 
7
 
 (2). The regulatory
complexes provide the specificity of polypeptide recogni-
tion. They also open the gated channel formed by the
outer ring of 20S proteasomes to control substrate access to
the catalytic chamber (3). Substrates of 26S proteasomes are
largely targeted to 19S regulatory subunits by the addition
of polyubiquitin chains (4). Three of the 
 
 
 
 subunits (
 
 
 
1,
 
 
 
2, 
 
 
 
5) of 20S proteasomes are known to possess protease
activity. Exposing cells to IFN-
 
 
 
 induces the synthesis of
alternatives for these subunits (respectively, LMP2,
MECL1, LMP7) that together are incorporated into an al-
ternative form of proteasomes known as immunoprotea-
somes (5).
Differences in the cleavage patterns of standard and im-
munoproteasomes have been demonstrated using purified
20S proteasomes and synthetic peptide substrates. Although
there were several conflicts in the original reports, it now
appears that in general, 20S immunoproteasomes are more
adept at producing peptides with hydrophobic and posi-
tively charged COOH-terminal residues. These are pre-
cisely the types of residues preferred by class I molecules
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(for a review, see reference 6). More recently, these find-
ings have been extended to the generation of defined pep-
tides by APCs (7–11).
The most direct method for studying the influence of
immunoproteasomes on immune responses in vivo
 
 
 
is to
compare wild-type mice to mice with targeted knockout
of genes encoding the immunoproteasome subunits. Al-
though mice lacking either LMP2 or LMP7 have been
available for several years, characterization of their T
 
CD8
 
 
 
responses has been performed at a fairly rudimentary level,
both in the methods used for enumeration of T
 
CD8
 
 
 
 re-
sponses and the number of determinants surveyed. The ef-
fects of the targeted disruptions on the immunodominance
hierarchy of T
 
CD8
 
 
 
 responding to a viral infection remain
to be characterized.
Immunodominance is the term given to the universal
phenomenon that only a small percentage of the multitude
of peptides present in a given antigen elicit T
 
CD8
 
 
 
 re-
sponses. Even among the chosen few, the numbers of re-
sponding T
 
CD8
 
 
 
 can vary enormously. The mechanisms
underlying immunodominance have recently come under
increased scrutiny because of its obvious importance for
vaccine design and T
 
CD8
 
 
 
-determinant prediction (for a re-
view, see reference 12). The rekindled interest is also due
to technological advances in T cell quantitation, such as the
introduction of intracellular cytokine staining (ICS; refer-
ence 13) and MHC-peptide tetramers (14). This has en-
abled direct counting of multiple specific CTL directly ex
vivo without the intervening in vitro culture that can skew
the true frequencies of responding cells. With the improved
technology, it is clear that greater numbers of determinants
are recognized by T
 
CD8
 
 
 
 than originally believed. Thus,
understanding the rules of determinant hierarchy becomes
an even more interesting (and difficult) problem. In this
study, we have used LMP2
 
 
 
/
 
 
 
 mice to examine the effects
of immunoproteasomes on the immunodominance hierar-
chy in the T
 
CD8
 
 
 
 response to influenza virus (IV) infection.
 
Materials and Methods
 
Cell Culture.
 
The DC cell line DC2.4 (H-2
 
b
 
; provided by Dr.
K. Rock, University of Massachusetts Medical School, Worcester,
MA; reference 15) and the thymoma cell line EL-4 were main-
tained in RPMI 1640 containing 10% fetal calf serum, 5 
 
 
 
 10
 
 
 
5 
 
M
2-mercaptoethanol, antibiotics, and 2 mM glutamine (RP-10). To
generate Con A or LPS blasts, 2 
 
 
 
 10
 
7
 
 spleen cells were cultured
with RP-10 medium in 6-well plates in the presence of 5 
 
 
 
g/ml
of Con A or LPS for 48 h. T
 
CD8
 
 
 
 were stimulated and maintained
in RP-10 medium supplied with 10 U/ml recombinant human
IL-2 (see below). Peritoneal exudate cells were harvested from
mice 3 d after intraperitoneal injection with 1 ml thioglycollate.
Dendritic cells were prepared as described (16).
 
mAbs and Other Reagents.
 
All mAbs used for flow cytometry
were purchased from BD PharMingen. All were fluorescein la-
beled except anti-CD8
 
 
 
 which was Cy-Chrome labeled. PE-
labeled D
 
b
 
-NP
 
366–374
 
-tetramers were provided by the MHC Tet-
ramer Core Facility of National Institute of Allergy and Infectious
Diseases, National Institutes of Health. Anti-CD4 mAb culture
supernatants from hybridoma GK1.5 (TIB 205; American Type
 
Culture Collection) and unlabeled anti-B220 Ab RA3-6B2 (BD
PharMingen) were used to coat M450 Dynal beads (Dynal) for
depleting CD4
 
 
 
 cells and B220
 
 
 
 expressing NK cells when estab-
lishing T
 
CD8
 
 
 
 lines.
 
Mice, Viruses, and CTL Stimulation.
 
C57BL/J6 (B6) mice and
B6.SJL-ptprc (B6.SJL) mice, which carry a CD45.1 marker, were
purchased from Taconic. B6.LMP2
 
 
 
/
 
  
 
mice were provided by L.
Van Kaer (Vanderbilt University, Nashville, TN) and were main-
tained under barrier conditions by Taconic. For priming, 8–10-
wk-old female mice were infected with 600 hemagglutination
units (HAU) of IV A/Puerto Rico/8/34 by intraperitoneal injec-
tion. IVs were propagated in the allantoic cavity of 10-d embryo-
nated chicken eggs. Splenic and peritoneal cells were generally
prepared 7 d after priming unless otherwise indicated. For gener-
ation of T
 
CD8
 
 
 
 lines, animals were generally used 
 
 
 
30 d after
priming. T
 
CD8
 
 
 
 stimulation was always carried out in RP-10 with
10 U/ml recombinant human IL-2. In brief, 3 
 
 
 
 10
 
7
 
 splenocytes
were stimulated with 1/20–1/25 the number of IV-infected or
peptide-pulsed APCs, irradiated with 200 Gy. Stimulated live T
cells were harvested through Ficoll-Hypaque gradient and en-
riched for CD8
 
 
 
 cells by depleting B220
 
 
 
 and CD4
 
 
 
 cells using
mAb-coated M-450 Dynal beads (Dynal).
 
Intracellular Cytokine and Tetramer Staining.
 
CTL activities
were tested either with ICS using peptides corresponding to the
known immunodominant and subdominant determinants in H-2
 
b
 
–
restricted response to influenza or assayed with D
 
b
 
-NP
 
366–374
 
-
tetramers. ICS was performed as described (17). In brief, splenic or
peritoneal cells were incubated with synthetic peptides at 0.5–1
 
 
 
M for 2 h at 37
 
 
 
C in Iscove’s modified DMEM supplemented
with 10% FBS. After addition of brefeldin A (BFA) to a concen-
tration of 10 
 
 
 
g/ml, cells were incubated for an additional 4 h at
37
 
 
 
C. Cells were then incubated on ice with Cy-labeled anti-
CD8a and PE-labeled anti-CD45.1 for 1 h, washed, and fixed
with 1% paraformaldehyde. Cells were then incubated in the pres-
ence of 0.2% saponin (Calbiochem) with fluorescein-labeled anti–
IFN-
 
 
 
. Tetramer staining was performed at room temperature for
1 h in the presence of Cy-Chrome–labeled anti-CD8 (BD
PharMingen). For ICS or tetramer staining, 100,000–300,000
cells were analyzed on a FACScan™ (Becton Dickinson). Total
Ag-specific cell numbers were calculated using Ag-specific per-
centage of total CD8
 
 
 
 cells multiplied by the total T
 
CD8
 
 
 
 percent-
age of total spleen or peritoneal cells acquired on the FACS
 
®
 
.
 
Infection of Cells for Antigen Presentation Kinetic Assay.
 
Cells
were washed with Autopow (Life Technologies) supplemented
with 0.1% BSA, 25 mM Hepes, and adjusted to pH 6.6, and re-
suspended in the same buffer containing 60 HAU IV per 10
 
6
 
 cells
and incubated for 1 h at 37
 
 
 
C in 96-well plates before adding
T
 
CD8
 
 
 
 in 200 
 
 
 
l of RP-10. BFA was then added at different time
points to a final concentration of 10 
 
 
 
g/ml. 2 h after the last ad-
dition of BFA, cells were harvested and T cell activation was de-
termined by ICS staining as described above.
 
Peptides and Binding Assays.
 
All peptides were synthesized,
HPLC purified, and analyzed by mass spectrometry by or under
the supervision of the Biologic Resource Branch, National Insti-
tutes of Allergy and Infectious Diseases, National Institutes of
Health. All peptides were 
 
 
 
95% purity. Peptides were dissolved
in DMSO at 1 mM as stock solutions and stored at 
 
 
 
30
 
 
 
C.
 
Naive T
 
CD8
 
 
 
 Precursor Transfer.
 
Splenocytes were T cell en-
riched with anti-CD90 (Thy1.2)-coated microbeads (Miltenyi
Biotec). Generally, 
 
 
 
85% purity was achieved as assessed by flow
cytometry. 
 
 
 
1.5 
 
 
 
 10
 
7
 
 purified cells were transferred into a na-
ive host animal intravenously. After transfer, animals were imme-
diately primed intraperitoneally with IV. 7 d later, the responses 
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of both host and donor cell population were followed with
CD45.1 Ab specific for B6.SJL cells or CD45.2 Ab specific for
normal B6 cells.
 
Transgenic TCR T
 
CD8
 
 
 
 Transfer.
 
B6 or LMP2
 
 
 
/
 
 
 
 mice were
irradiated with 800 rads 2 d before T cell transfer. On the day of
transfer, mice (in groups of three) were infected by intraperito-
neal injection with IV HK/X31 (X31), A/NT60/68 (NT60), or
left uninfected. 5 h later, mice were given 5 
 
 
 
 10
 
6
 
 transgenic T
cells by intravenous injection. T cells were purified from homog-
enized spleen and lymph nodes (popliteal, inguinal, brachial, axil-
lary, and superficial cervical) obtained from F5 mice. Purification
entailed Ficoll gradient centrifugation followed by positive selec-
tion of Thy1.2 (CD90) positive as described above. 16 h after T
cell transfer, spleens were removed, homogenized, and centri-
fuged in a Ficoll gradient to yield viable mononuclear cells. Cells
were incubated in 20% normal mouse serum and mAb 2.4G2 (Fc
block) supernatant for 20 min before staining with directly conju-
gated FITC-labeled Abs to CD69, CD25, or CD62L. Cells were
analyzed by flow cytometry, gating on CD8
 
 
 
V
 
 
 
 11
 
 
 
 cells (the
V
 
 
 
 class of the F5 TCR) to ascertain the cell surface levels of
these T cell activation markers.
 
Results and Discussion
 
We first compared anti-IV T
 
CD8
 
 
 
 responses of wild-type
B6 to that of LMP2
 
 
 
/
 
 
 
 mice. After intraperitoneal infec-
 
tion, peritoneal exudate cells and splenocytes were assayed
from 4 to 9 d after infection for responses to six of the
seven defined peptides from IV gene products (see Table I)
that are known to be recognized by T
 
CD8
 
 
 
 from IV-
infected H-2
 
b
 
 mice (18; and unpublished data). Two deter-
minants, NP
 
366–374
 
 and PA
 
224–233
 
, have been reported to
dominate local and splenic responses of B6 mice after intra-
nasal infection with influenza. As seen in Fig. 1, the same
peptides dominate the local and splenic response after intra-
peritoneal infection. LMP2
 
 
 
/
 
 
 
 mice exhibited dramatic
differences from B6 mice. Responses to NP366–374 and
PA224–233 were greatly reduced whereas responses to
NS2114–122 and PB1F262–70 were enhanced. This effect was
particularly prominent with peritoneal TCD8 . Overall, the
LMP2 /  response was less vigorous both in the percent-
age of responding virus-specific TCD8 , and in the overall
number of responding cells. Of interest,  1/2 the number
of total TCD8  were recovered from infected LMP2 / 
mice compared with B6 mice.
This experiment indicates that immunoproteasomes play
an important role in determining the immunodominance
hierarchy (summarized in Table I). To distinguish the con-
tributions to this phenomenon of TCD8  repertoire ver-
sus antigen presentation, we examined the response of
Figure 1. Immunodominance hierarchy to IV infection
in B6 and LMP2 /  mice. Spleen and peritoneal cells were
prepared at various times after IV priming and their determi-
nant-specific responses were assessed by ICS using a panel of
synthetic peptides corresponding to defined H-2b–restricted
determinants. All responses were normalized by subtracting
background values obtained using cells receiving no pep-
tides. In this experiment, twice as many TCD8  were recov-
ered from B6 mice than from LMP2 /  mice.1322 Immunoproteasomes Influence Immunodominance
LMP2 /  mice after transfer of TCD8  from wild-type
mice. To enable discrimination of host versus donor cells
we used B6.SJL mice as donors. TCD8  from these mice ex-
press a marker (CD45.1) absent in B6 mice that can be de-
tected by mAb staining. CD90 (Thy1.2)-enriched spleno-
cytes from B6.SJL mice were transferred into either B6 or
LMP2 /  mice that were then infected with IV. Spleen
and peritoneal cells were harvested 7 d later and analyzed
by ICS using the panel of seven IV peptides or by staining
with PE-labeled Db-NP366–374 tetramers.
The left panel of Fig. 2 A shows the typical pattern of
tetramer staining of splenocytes in obtained from IV-
infected B6 mice; in the mouse examined, 7% of TCD8  are
tetramer positive. The middle panel shows that of the tet-
ramer-positive TCD8  in this spleen, only 2% are derived
from donor cells. The right panel shows the summarized
composite results of tetramer-positive cells for host- (white
Table I. Properties of H-2b–restricted IV-derived Determinants
Determinant Sequence
ID rank
LMP2 /  B6 
Restriction
element
PA224–233 SSLENFRAYV 51 D b
NP366–374 ASNENMETM 32 D b
PB1F262–70 LSLRNPILV 13 D b
NS2114–121 RTFSFQLI 26 K b
M1128–135 MGLIYNRM 57 K b
PB1703–711 SSYRRPVGI 33 K b
PB2198–206 ISPLMVAYM 53 K b
The ID rank is based on averaging the frequency of splenic and
peritoneal TCD8  following intraperitoneal infection with PR8.
Determinants with similar immunogenicity are assigned the same rank.
Figure 2. IV-specific responses of naive host and
donor T cells. CD90-enriched spleen cells from
naive B6.SJL were transferred into either normal
B6 or LMP2 /  mice followed by IV infection.
After 7 d, both host and donor cells were assayed
for ICS and CD45.1 expression. Donor- and host-
derived NP366–374-specific TCD8  were also tested
for NP366–374-tetramer staining and CD45.1 expres-
sion. Panel A shows typical NP366–374-tetramer
staining of spleen cells (left). The background-posi-
tive staining on naive B6 spleen cells was  0.5%.
Tetramer-positive cells were gated and displayed as
CD45.1 positive (donor) and negative (host) (mid-
dle). The percentage of each group was then plot-
ted as the fraction of tetramer positive cells (right).
B and C show, respectively, the determinant-spe-
cific hierarchy of host and donor cells. Both are
shown as the total antigen-specific cell number, ei-
ther per spleen or per peritoneum after subtracting
background values obtained from the no peptide
control for each mouse. Data represent the average
values from two individual mice.1323 Chen et al. Brief Definitive Report
bars) and donor-derived (filled bars) TCD8  in B6 and
LMP2 /  mice. Remarkably, donor cells comprise 50% of
the tetramer-positive response in LMP2 /  mice: more
than 10-fold higher than in B6 mice. These findings were
confirmed by ICS (Fig. 2, B and C), which demonstrated a
much greater host TCD8  response to NP366–374 in B6 mice,
and conversely a much greater ( sixfold) donor NP366–374–
specific TCD8  response in spleens of LMP2 /  mice. Note
the 20-fold difference in scale used to display the results of
host and donor cells. This difference in abundance between
host and donor cells can be attributed to both the number
of TCD8  used for transfer ( 1/10 the amount of TCD8 
present in mice), and also an anticipated loss in cells due
to imperfect trafficking to spleen and peritoneum. The
marked expansion of transferred naive NP366–374–specific
TCD8  in LMP2 /  mice indicates that deficiencies in the
TCD8  repertoire are a major factor in the limited response
of LMP2 /  mice to NP366–374.
Examination of the results for host cell responses to the
six other determinants tested in this experiment reveals that
the typical immunodominance hierarchies of B6 and
LMP2 /  host cells were basically unaltered by the cell
transfer (compare Fig. 2 B with Fig. 1). In B6 mice, NP366–374
and PA224–233-specific CTL remain dominant in both peri-
toneal and spleen cell responses. In LMP2 /  mice, TCD8 
specific for PB1F262–70 and NS2114–122 dominate the re-
sponse. Notably, the total number of responding host cells
in LMP2 /  mice is much less than in B6 mice, particularly
in the spleen.
In B6 mice, the response of donor cells basically mir-
rored the host cell response (Fig. 2 C). There were several
interesting differences in the response of donor cells in
LMP2 /  mice compared with B6 mice. First, there was
the noticeable increase in the response of splenic NP366–374-
specific cells observed with tetramers. This was somewhat
less apparent in the peritoneal cavity, perhaps due to
increased immunodomination from PB1F262–70-specific
TCD8 . Second, with one important exception, more do-
nor cells specific for each determinant were recovered from
LMP2 /  mice than B6 mice, indicating that antigen pre-
sentation is not limiting for these determinants. This effect
was most marked with PB1F262–70-specific TCD8 . Third,
for the exceptional determinant, PA224–233, less  specific
TCD8  were recovered from both peritoneal and splenic
populations in LMP2 /  mice than from B6 mice, point-
ing to a defect in antigen presentation in these mice.
To confirm that presentation of NP366–374 was similar in
wild-type and LMP2 /  mice, we adoptively transferred
purified TCD8  from F5 TCR transgenic mice (19). Mice
were then infected intraperitoneally with NT60 IV, which
expresses NP with the cognate Db-restricted NP366–374 pep-
tide (ASNENMDAM) recognized by F5 TCD8 . As a con-
trol, mice were infected with X31, which expresses NP
with the non–cross-reactive ASNENMETM peptide. Peri-
toneal exudate cells were harvested 16 h after infection and
the activation state of F5 TCD8  was assessed by enhanced
expression of CD25 and diminished expression of CD62
(Fig. 3). Importantly, F5 cells were activated at similar lev-
els after transfer into LMP2 /  and wild-type mice. The
antigen specificity of this activation is shown by the similar-
ity between F5 cells recovered from X31 infected mice and
uninfected mice.
We next performed an adoptive transfer experiment us-
ing LMP2 /  donor splenocytes and B6.SJL recipients
(Fig. 4). The response of host TCD8  was similar to unma-
nipulated mice. Despite these robust responses, we failed to
detect activation of the transferred cells. This finding can-
not be attributed to differences in the handling or purifica-
tion of the transferred TCD8 , as we observed similar results
in three separate experiments. Rather, it is consistent with a
general defect in the ability of LMP2 /  mice to mount an
IV-specific response that is exacerbated in the presence of
TCD8  from normal mice.
Finally, we examined the capacity of LMP2 /  and
wild-type APCs to present endogenous IV antigens to anti-
gen-specific TCD8  lines. To avoid uncertainties associated
with the clonal variation of established APC cell lines, we
Figure 3. Activation of adoptively transferred transgenic TCD8 . Puri-
fied TCD8  from F5 TCR transgenic mice were transferred into B6 or
LMP2 /  mice infected with NT60, X31 (control), or left uninfected as
indicated. Cells were assessed by flow cytometry for activation based on
enhanced binding of a CD25-specific mAb or decreased binding of a
CD62-specific mAb.
Figure 4. IV-specific responses of transferred naive LMP2 /  T cells.
CD90-enriched spleen cells from naive LMP2 /  mice were transferred
into either naive B6.SJL or B6 mice followed by IV priming. 7 d later,
both the host and donor cells were assayed for ICS and CD45.2 expres-
sion. The determinant-specific hierarchy among host (left) and donor
(right) splenic TCD8  is shown. Data were processed as described in the
Fig. 2 legend. Note the 10-fold difference in the Ag-specific TCD8  scale.1324 Immunoproteasomes Influence Immunodominance
used cell populations obtained directly from mice. APCs
were incubated with BFA at various times after infection
and antigen presentation was quantitated by the capacity of
the cells to trigger determinant-specific TCD8  lines as mea-
sured by ICS. In additional experiments (not shown), we
found that this assay parallels presentation kinetics as mea-
sured by 51Cr release, which itself is proportional to the
number of peptide-class I complexes recovered from cells
(20). As seen in Fig. 5 A, Con A blasts from wild-type and
LMP2 /  mice showed a similar kinetics of presenting
NP366–374. By contrast, LMP2 /  blasts presented PB1F262–70
much more rapidly than B6 blasts. This provides the sec-
ond published example of immunoproteasomes interfering
with production of a specific determinant (7). Unfortu-
nately, we were not able to compare the presentation of
PA224–233 in this assay due to its very poor presentation in
vitro even under optimal circumstances (unpublished data).
The identical presentation of NP366–374 by wild-type and
knockout cells was surprising, as it was reported that
LMP2 /  LPS blasts and peritoneal exudate cells exhibit
defective presentation of this determinant (21). We there-
fore repeated this experiment using LPS blasts, peritoneal
exudate cells, and dendritic cells prepared from wild-type
and LMP2 /  mice (Fig. 5 B). Once again, we failed to
observe a significant difference in the presentation of this
determinant.
Taken together, these findings indicate that in LMP2 / 
mice the: (a) decreased response to NP366–374 is based prin-
cipally, if not solely, on defects in the TCD8  repertoire; (b)
decreased response to PA224–233 is due principally to defects
in antigen presentation; and (c) enhanced response to
PB1F262–70 is probably due at least in part to enhanced gen-
eration by standard proteasomes relative to immunoprotea-
somes.
Van Kaer et al. (21) previously reported that LMP2 / 
mice exhibit diminished responses to NP366–374. This was at-
tributed to a defect in antigen presentation based on the de-
creased abilities of LPS-activated splenocytes or peritoneal
exudate cells derived from LMP2 /  mice to activate a
NP366–374-specific T cell hybridoma. By contrast, we failed
to observe a similar defect in presentation by either LPS- or
Con A–activated splenocytes, peritoneal exudate cells, or
dendritic cells. We previously demonstrated that the kinetics
of presentation as determined using BFA reflects the number
of peptide class I complexes recovered from cells (20), and
we believe that the data in Fig. 5 demonstrate that there is
no significant difference between the capacities of wild-type
and LMP2 /  cells to generate NP366–374 from the PR8 NP.
As PA224–233 occupies the  -position in the B6 TCD8 
immunodominance hierarchy, its demotion in LMP2 / 
mice can influence the response to all of the other determi-
nants due to decreased immunodomination (17). Given the
opportunity to assume the  -position, the plunge of
NP366–374 down the immunodominance hierarchy is strik-
ing, and demonstrates the profound effect of LMP2 on the
anti-NP366–374 repertoire. The loss of immunodomination
exerted by these two determinants probably contributes to
the ascendence of PB1F262–70- and NS2114–122-specific
TCD8  in LMP2 /  mice. The enhanced presentation of
PB1F262–70 in LMP2 /  APCs probably contributes to its
rise to the  -position.
Our findings demonstrate that the loss of LMP2 has a
significant effect on the TCD8  repertoire. This is not
shocking given the observation that LMP2 /  mice exhibit
a specific deficit in the numbers of TCD8  relative to B6
mice. As LMP2 is expressed in the thymus (22), its absence
can affect the repertoire by influencing positive and/or
negative selection, as well as whatever effects it may exert
in the periphery. As LMP7 and MECL1 can assemble func-
tional proteasomes in the absence LMP2, albeit inefficiently
(23, 24), the characteristics of LMP2 /  mice provide a
minimal estimate of the role of immunoproteasomes on an-
tigen presentation and the TCD8  repertoire. That deficien-
cies in antigen processing can influence the TCD8  reper-
toire was previously established in studies of TAP /  mice
(25, 26). Moreover, the effect of LMP2 on repertoire de-
velopment parallels similar findings in MHC class II–medi-
ated selection of the TCD4  repertoire, where targeted dis-
ruptions in genes encoding a protease (cathepsin L) that
contributes to antigen processing or a molecule (H-2M)
that aids peptide loading of class II molecules have been
shown to modify the repertoire (27–29).
Figure 5. Kinetics of antigen presentation of B6 and LMP2 /  cells.
The efficiency of antigen presentation was determined by the capacity of
cells to activate short-term antigen-specific TCD8  as determined by ICS.
(A) Kinetics of antigen presentation of Con A blasts to NP366–374-specific
TCD8  (left) or PB1F262–70-specific TCD8  (right). (B) Kinetics of antigen
presentation of cells as indicated to NP366–374-specific TCD8 . PEC, peri-
toneal cavity.1325 Chen et al. Brief Definitive Report
It is interesting that the overall number of TCD8  re-
sponding to IV was decreased in LMP2 /  mice. Poten-
tially, this could be due to our failure to provide the proper
determinants to LMP2 /  TCD8  during restimulation for
the ICS assay. This possibility is unlikely, however, as a
large difference was observed in head to head comparisons
of ex vivo TCD8  activated for ICS staining by IV-infected
splenocytes from autologous mice as APCs (data not
shown). Rather, it appears that the absence of LMP2 de-
creases the ability of TCD8  to respond to foreign antigens,
even to determinants that appear to be made equally by
standard proteasomes and immunoproteasomes. Consistent
with this finding, TCD8  from LMP2 /  mice failed to ex-
pand when transferred to B6 mice. Even if the lion’s share
of this effect is due to increased relative immunodomina-
tion by host TCD8  (as it probably is), it still points to a di-
minished capacity of LMP2 /  TCD8  to proliferate relative
to normal TCD8 .
The poor responsiveness of LMP2 /  TCD8  to IV dem-
onstrates that LMP2, and by inference immunoprotea-
somes, enhance the ability of TCD8  to respond to foreign
antigens. Although this is reassuring in terms of under-
standing the evolution of immunoproteasomes, this com-
fort comes at the cost of a mechanistic conundrum: how
can the absence of immunoproteasomes affect responses to
foreign determinants produced equally (or more) efficiently
by standard proteasomes? Immunoproteasomes may play a
role in TCD8  cell activation and proliferation. Addition-
ally, given that the selection of germ line TCR genes in
evolution occurred in the context of MHC molecules pre-
senting a peptide repertoire heavily influenced by immu-
noproteasomes, it is not hard to imagine that the repertoire
suffers when the selection is limited to peptides produced
by standard proteasomes. With the rapid advances in se-
quencing technology, it should be possible to directly com-
pare the naive TCD8  repertoire of normal mice and those
lacking immunoproteasomes.
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